Soluble CD40 Ligand Plasma Levels in Lung Cancer

Mario Roselli, Tommaso C. Mineo, Stefania Basili, Francesca Martini, Sabrina Mariotti, Simona Aloe, Girolamo Del Monte, Vincenzo Ambrogi, Antonella Spila, Raffaele Palmirotta, Roberta D'Alessandro, Giovanni Davì, Fiorella Guadagni, Patrizia Ferroni

Research output: Contribution to journalArticle

Abstract

Purpose: Tumor-induced platelet activation may cause the release of various cytokines, including CD40 ligand (CD40L). Activation of the CD40/CD40L pathway in human tumors may result in thrombin generation, which is known to be involved in angiogenesis. Thus, we investigated whether soluble (s)CD40L levels are increased in patients with lung cancer as a result of platelet and/or coagulation activation. Experimental Design: Citrated plasma samples were obtained from 120 patients with different stages and histotypes of lung cancer and 60 age- and sex-matched control subjects. sCD40L, sP-selectin (marker of platelet activation), prothrombin fragment 1 + 2, and thrombin-antithrombin III complex levels (both markers of coagulative activation) were measured in all samples. Results: Patients with lung cancer had median sCD40L levels higher than in control subjects (0.46 versus 0.13 ng/ml; P <0.0001), although correlation with the stage of disease was not evident. Nonetheless, sCD40L levels were significantly higher in squamous cancer compared with adenocarcinoma (0.75 versus 0.27 ng/ml; P <0.05). Moreover, median sCD40L levels were higher in stage IV compared with nonmetastatic squamous lung cancer (1.02 versus 0.61 ng/mi; P <0.05). sCD40L levels significantly correlated with sP-selectin (P <0.001), prothrombin fragment 1 + 2 (P <0.001), or thrombin-antithrombin III complex (P <0.05) in squamous lung cancer, but only sP-selectin (P = 0.011) was independently related to sCD40L. Conclusions: These findings indicate that elevated sCD40L levels can be preferentially found in patients with advanced squamous cancer and provide evidence that increased levels of this cytokine are associated to the occurrence of in vivo platelet activation.

Original languageEnglish
Pages (from-to)610-614
Number of pages5
JournalClinical Cancer Research
Volume10
Issue number2
DOIs
Publication statusPublished - Jan 15 2004

Fingerprint

CD40 Ligand
Lung Neoplasms
Platelet Activation
P-Selectin
Neoplasms
Cytokines
Selectins
Thrombin
Adenocarcinoma
Research Design
Blood Platelets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Roselli, M., Mineo, T. C., Basili, S., Martini, F., Mariotti, S., Aloe, S., ... Ferroni, P. (2004). Soluble CD40 Ligand Plasma Levels in Lung Cancer. Clinical Cancer Research, 10(2), 610-614. https://doi.org/10.1158/1078-0432.CCR-0348-03

Soluble CD40 Ligand Plasma Levels in Lung Cancer. / Roselli, Mario; Mineo, Tommaso C.; Basili, Stefania; Martini, Francesca; Mariotti, Sabrina; Aloe, Simona; Del Monte, Girolamo; Ambrogi, Vincenzo; Spila, Antonella; Palmirotta, Raffaele; D'Alessandro, Roberta; Davì, Giovanni; Guadagni, Fiorella; Ferroni, Patrizia.

In: Clinical Cancer Research, Vol. 10, No. 2, 15.01.2004, p. 610-614.

Research output: Contribution to journalArticle

Roselli, M, Mineo, TC, Basili, S, Martini, F, Mariotti, S, Aloe, S, Del Monte, G, Ambrogi, V, Spila, A, Palmirotta, R, D'Alessandro, R, Davì, G, Guadagni, F & Ferroni, P 2004, 'Soluble CD40 Ligand Plasma Levels in Lung Cancer', Clinical Cancer Research, vol. 10, no. 2, pp. 610-614. https://doi.org/10.1158/1078-0432.CCR-0348-03
Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S et al. Soluble CD40 Ligand Plasma Levels in Lung Cancer. Clinical Cancer Research. 2004 Jan 15;10(2):610-614. https://doi.org/10.1158/1078-0432.CCR-0348-03
Roselli, Mario ; Mineo, Tommaso C. ; Basili, Stefania ; Martini, Francesca ; Mariotti, Sabrina ; Aloe, Simona ; Del Monte, Girolamo ; Ambrogi, Vincenzo ; Spila, Antonella ; Palmirotta, Raffaele ; D'Alessandro, Roberta ; Davì, Giovanni ; Guadagni, Fiorella ; Ferroni, Patrizia. / Soluble CD40 Ligand Plasma Levels in Lung Cancer. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 2. pp. 610-614.
@article{d2453b80f1104534a6d7a697f0bc642d,
title = "Soluble CD40 Ligand Plasma Levels in Lung Cancer",
abstract = "Purpose: Tumor-induced platelet activation may cause the release of various cytokines, including CD40 ligand (CD40L). Activation of the CD40/CD40L pathway in human tumors may result in thrombin generation, which is known to be involved in angiogenesis. Thus, we investigated whether soluble (s)CD40L levels are increased in patients with lung cancer as a result of platelet and/or coagulation activation. Experimental Design: Citrated plasma samples were obtained from 120 patients with different stages and histotypes of lung cancer and 60 age- and sex-matched control subjects. sCD40L, sP-selectin (marker of platelet activation), prothrombin fragment 1 + 2, and thrombin-antithrombin III complex levels (both markers of coagulative activation) were measured in all samples. Results: Patients with lung cancer had median sCD40L levels higher than in control subjects (0.46 versus 0.13 ng/ml; P <0.0001), although correlation with the stage of disease was not evident. Nonetheless, sCD40L levels were significantly higher in squamous cancer compared with adenocarcinoma (0.75 versus 0.27 ng/ml; P <0.05). Moreover, median sCD40L levels were higher in stage IV compared with nonmetastatic squamous lung cancer (1.02 versus 0.61 ng/mi; P <0.05). sCD40L levels significantly correlated with sP-selectin (P <0.001), prothrombin fragment 1 + 2 (P <0.001), or thrombin-antithrombin III complex (P <0.05) in squamous lung cancer, but only sP-selectin (P = 0.011) was independently related to sCD40L. Conclusions: These findings indicate that elevated sCD40L levels can be preferentially found in patients with advanced squamous cancer and provide evidence that increased levels of this cytokine are associated to the occurrence of in vivo platelet activation.",
author = "Mario Roselli and Mineo, {Tommaso C.} and Stefania Basili and Francesca Martini and Sabrina Mariotti and Simona Aloe and {Del Monte}, Girolamo and Vincenzo Ambrogi and Antonella Spila and Raffaele Palmirotta and Roberta D'Alessandro and Giovanni Dav{\`i} and Fiorella Guadagni and Patrizia Ferroni",
year = "2004",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-0348-03",
language = "English",
volume = "10",
pages = "610--614",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Soluble CD40 Ligand Plasma Levels in Lung Cancer

AU - Roselli, Mario

AU - Mineo, Tommaso C.

AU - Basili, Stefania

AU - Martini, Francesca

AU - Mariotti, Sabrina

AU - Aloe, Simona

AU - Del Monte, Girolamo

AU - Ambrogi, Vincenzo

AU - Spila, Antonella

AU - Palmirotta, Raffaele

AU - D'Alessandro, Roberta

AU - Davì, Giovanni

AU - Guadagni, Fiorella

AU - Ferroni, Patrizia

PY - 2004/1/15

Y1 - 2004/1/15

N2 - Purpose: Tumor-induced platelet activation may cause the release of various cytokines, including CD40 ligand (CD40L). Activation of the CD40/CD40L pathway in human tumors may result in thrombin generation, which is known to be involved in angiogenesis. Thus, we investigated whether soluble (s)CD40L levels are increased in patients with lung cancer as a result of platelet and/or coagulation activation. Experimental Design: Citrated plasma samples were obtained from 120 patients with different stages and histotypes of lung cancer and 60 age- and sex-matched control subjects. sCD40L, sP-selectin (marker of platelet activation), prothrombin fragment 1 + 2, and thrombin-antithrombin III complex levels (both markers of coagulative activation) were measured in all samples. Results: Patients with lung cancer had median sCD40L levels higher than in control subjects (0.46 versus 0.13 ng/ml; P <0.0001), although correlation with the stage of disease was not evident. Nonetheless, sCD40L levels were significantly higher in squamous cancer compared with adenocarcinoma (0.75 versus 0.27 ng/ml; P <0.05). Moreover, median sCD40L levels were higher in stage IV compared with nonmetastatic squamous lung cancer (1.02 versus 0.61 ng/mi; P <0.05). sCD40L levels significantly correlated with sP-selectin (P <0.001), prothrombin fragment 1 + 2 (P <0.001), or thrombin-antithrombin III complex (P <0.05) in squamous lung cancer, but only sP-selectin (P = 0.011) was independently related to sCD40L. Conclusions: These findings indicate that elevated sCD40L levels can be preferentially found in patients with advanced squamous cancer and provide evidence that increased levels of this cytokine are associated to the occurrence of in vivo platelet activation.

AB - Purpose: Tumor-induced platelet activation may cause the release of various cytokines, including CD40 ligand (CD40L). Activation of the CD40/CD40L pathway in human tumors may result in thrombin generation, which is known to be involved in angiogenesis. Thus, we investigated whether soluble (s)CD40L levels are increased in patients with lung cancer as a result of platelet and/or coagulation activation. Experimental Design: Citrated plasma samples were obtained from 120 patients with different stages and histotypes of lung cancer and 60 age- and sex-matched control subjects. sCD40L, sP-selectin (marker of platelet activation), prothrombin fragment 1 + 2, and thrombin-antithrombin III complex levels (both markers of coagulative activation) were measured in all samples. Results: Patients with lung cancer had median sCD40L levels higher than in control subjects (0.46 versus 0.13 ng/ml; P <0.0001), although correlation with the stage of disease was not evident. Nonetheless, sCD40L levels were significantly higher in squamous cancer compared with adenocarcinoma (0.75 versus 0.27 ng/ml; P <0.05). Moreover, median sCD40L levels were higher in stage IV compared with nonmetastatic squamous lung cancer (1.02 versus 0.61 ng/mi; P <0.05). sCD40L levels significantly correlated with sP-selectin (P <0.001), prothrombin fragment 1 + 2 (P <0.001), or thrombin-antithrombin III complex (P <0.05) in squamous lung cancer, but only sP-selectin (P = 0.011) was independently related to sCD40L. Conclusions: These findings indicate that elevated sCD40L levels can be preferentially found in patients with advanced squamous cancer and provide evidence that increased levels of this cytokine are associated to the occurrence of in vivo platelet activation.

UR - http://www.scopus.com/inward/record.url?scp=10744233644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744233644&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-0348-03

DO - 10.1158/1078-0432.CCR-0348-03

M3 - Article

C2 - 14760083

AN - SCOPUS:10744233644

VL - 10

SP - 610

EP - 614

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -